OR WAIT null SECS
Low doses of clobetasone butyrate drops are safe and effective for Sj?gren syndrome (SS), claims an investigation.
Low doses of clobetasone butyrate drops are safe and effective for Sjögren syndrome (SS), claims an investigation.
A team headed by Dr P. Aragona, Ocular Surface Unit, Department of Surgical Specialties, University of Messina, Italy, conducted a prospective, double-masked, randomized, placebo-controlled study on 40 SS patients.
All subjects were randomized into two treatment groups: a 2% polyvinylpyrrolidone eyedrops and placebo group (Group 1) and a 2% polyvinylpyrrolidone and 0.1% clobetasone butyrate group (Group 2). Treatment was administered for 30 days with visits at enrolment, baseline, day 15, day 30, and after 15 days post-treatment.
Each visit consisted of a symptoms questionnaire, fundus examinations and measurements of tear film break-up time corneal fluorescein stain, lissamine green stain, conjunctival impression cytology for human leukocyte antigen-DR (HLA-DR) expression and IOP.
There were no recorded changes in IOP or fundus examination in either group at any time. However, group 1 presented a statistically significant amelioration of symptoms and reduction of HLA-DR expression.
Group 2 demonstrated a statistically significant improvement in corneal and conjunctival stain at day 15, compared to baseline measurements and group 1 results. HLA-DR expression and epithelial cells area in group 2 were statistically significantly reduced compared to baseline and group 1.
Clobetasone butyrate, when administered at a low dosage of 0.1%, is a safe and effective treatment for SS. It was also concluded that anti-inflammatory therapy is crucial for the treatment of SS dry eye.
To read more please visit the European Journal of Ophthalmology.